The impact of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in the phase III TAGS trial

Kohei Shitara,1 Ben George,2 Julien Taieb,3 Raghav Sundar,4 Marwan G. Fakih,5 Lukas Makris,6 Karim A. Benhadji,7 Michele Ghidini8

1National Cancer Center Hospital East, Chiba, Japan; 2Medical College of Wisconsin, Milwaukee, WI; 3Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France; 4National University Health System, Singapore; 5City of Hope Comprehensive Cancer Center, Duarte, CA; 6Stathmi, Inc., New Hope, PA; 7Taiho Oncology, Inc., Princeton, NJ; 8Azienda Ospedaliera di Cremona, Cremona, Italy